Landos Biopharma, Inc.
Lanthionine synthetase C-like 2-based therapeutics
Last updated:
Abstract:
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.
Status:
Grant
Type:
Utility
Filling date:
20 Dec 2018
Issue date:
3 Dec 2019